Location: United States, California, Los Angeles
Employees: 11-50
Total raised: $5M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Checkmate ... | checkmatec... |
| 06.05.2025 | KidsX | kidsx.heal... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.12.2021 | - | $5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 31.01.2023 | NeuroSigma Announces Strategic Digital Marketing Partnership with Data360 | NeuroSigma, a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, announced the commencement of a strategic digital marke... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 08.12.2021 | NeuroSigma Announces a $5 Million Equity Investment by KT Corporation | Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KT Significant investment in NeuroSigma’s digital health and neuro-electronics platform LOS ANGELES, Dec. 08, 2021 (GLOBE NEWSWI... |
| 08.12.2021 | NeuroSigma Announces a $5 Million Equity Investment by KT Corporation | Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KT Significant investment in NeuroSigma’s digital health and neuro-electronics platform LOS ANGELES, Dec. 08, 2021 (GLOBE NEWSWI... |
| 11.03.2021 | NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio | |
| 22.01.2021 | NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System | |
| 17.12.2020 | NeuroSigma's Monarch eTNS for Pediatric ADHD Featured in MD+DI's List of the 10 Wearable Medical Devices that Redefined Healthcare | |
| 01.10.2014 | UCLA spinout NeuroSigma seeks $50m in IPO | NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout’s noninvasive system to treat drug-resistant epilepsy. NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for betw... |
| 27.08.2014 | Neurosigma Files For IPO | Los Angeles-based NeuroSigma, a developer of medical devices aimed at treating epilepsy and depression, has filed for an IPO, saying that it is looking to raise up to $50M on the public markets. The company said it has applied to list on th... |